From: Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial
Stage dose and route
Patients, n(active:placebo)
SAD stage dose, route (cohort)
0.3 IV (A)
4:1
1.0 IV (B)
1.0 SC (C)
3.0 IV (D)
3.0 SC (E)
5.0 IV (F)
MAD stage dose, route (cohort)
1.0 SC (G)
8:2
3.0 SC (H)
16:4
5.0 IV (I)